Free Trial

Ocugen (OCGN) Financials

Ocugen logo
$0.79 -0.04 (-4.57%)
As of 10:48 AM Eastern
This is a fair market value price provided by Massive. Learn more.
Annual Income Statements for Ocugen

Annual Income Statements for Ocugen

This table shows Ocugen's income and expenses over time, based on annual financial data. All values are USD millions unless otherwise specified.

Metric 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025
Period end date 12/31/2015 12/31/2016 12/31/2017 12/31/2018 12/31/2019 12/31/2020 12/31/2021 12/31/2022 12/31/2023 12/31/2024 12/31/2025
Net Income / (Loss) Attributable to Common Shareholders
-32 -14 -22 -18 -20 -34 -58 -87 -63 -54 -68
Consolidated Net Income / (Loss)
-32 -16 -26 -18 -20 -22 -58 -87 -63 -54 -68
Net Income / (Loss) Continuing Operations
-32 -16 -26 -18 -20 -22 -58 -87 -63 -54 -68
Total Pre-Tax Income
-32 -16 -26 -18 -20 -22 -58 -89 -66 -54 -68
Total Operating Income
-32 -30 -25 -16 -14 -21 -58 -89 -66 -55 -63
Total Gross Profit
0.00 0.00 0.00 0.00 0.00 0.04 0.00 2.49 6.04 4.06 4.41
Total Revenue
0.00 0.00 0.00 0.00 0.00 0.04 0.00 2.49 6.04 4.06 4.41
Operating Revenue
0.00 0.00 0.00 - 0.00 0.04 - 2.49 6.04 4.06 4.41
Total Cost of Revenue
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Operating Expenses
32 30 25 16 14 21 58 92 72 59 67
Selling, General & Admin Expense
8.27 8.53 9.38 5.82 6.08 7.97 23 35 32 27 28
Research & Development Expense
23 22 16 10 8.09 13 35 56 40 32 40
Total Other Income / (Expense), net
-0.22 14 -1.46 -2.08 -6.08 -0.54 -0.39 0.00 0.00 0.70 -4.93
Interest Expense
0.13 - 0.00 3.75 1.77 0.72 - - - 0.69 5.19
Interest & Investment Income
- -0.06 0.13 0.02 - - - - - 1.25 0.92
Other Income / (Expense), net
-0.08 14 -1.60 1.65 -4.31 0.18 -0.39 - - 0.14 -0.66
Basic Earnings per Share
($2.42) ($0.97) ($0.99) ($3.67) ($1.46) ($0.31) ($0.30) ($0.40) ($0.26) ($1.00) ($0.23)
Weighted Average Basic Shares Outstanding
13.23M 14.26M 22.67M 4.96M 13.89M 112.24M 195.01M 214.60M 244.33M 325.74M 300.17M
Diluted Earnings per Share
($2.42) ($2.18) ($0.99) ($3.67) ($1.46) ($0.31) ($0.30) ($0.40) ($0.26) ($1.00) ($0.23)
Weighted Average Diluted Shares Outstanding
13.23M 14.39M 22.67M 4.96M 13.89M 112.24M 195.01M 214.60M 244.33M 325.74M 300.17M
Weighted Average Basic & Diluted Shares Outstanding
13.23M 22.17M 28.69M 4.96M 13.89M 112.24M 199.49M 226.42M - 292.01M 327.90M

Quarterly Income Statements for Ocugen

This table shows Ocugen's income and expenses over time, based on quarterly financial data. All values are USD millions unless otherwise specified.

Metric Q1 2024 Q2 2024 Q3 2024 Q4 2024 Q1 2025 Q2 2025 Q3 2025 Q4 2025 Q1 2026 Q2 2026 Q3 2026
Period end date 3/31/2024 6/30/2024 9/30/2024 12/31/2024 3/31/2025 6/30/2025 9/30/2025 12/31/2025 3/31/2026 6/30/2026 9/30/2026
Net Income / (Loss) Attributable to Common Shareholders
-12 -15 -13 -19 -15 -15 -20 -18 -19 -25 -3.60
Consolidated Net Income / (Loss)
-12 -15 -13 -14 -15 -15 -20 -18 -19 -25 -3.60
Net Income / (Loss) Continuing Operations
-12 -15 -13 -14 -15 -15 -20 -18 -19 -25 -3.60
Total Pre-Tax Income
-12 -15 -13 -14 -15 -15 -20 -18 -19 -25 -3.60
Total Operating Income
-12 -15 -13 -14 -15 -14 -18 -17 -18 -16 -18
Total Gross Profit
1.01 1.14 1.14 0.76 1.48 1.37 1.75 -0.19 1.53 1.49 1.95
Total Revenue
1.01 1.14 1.14 0.76 1.48 1.37 1.75 -0.19 1.53 1.49 1.95
Operating Revenue
1.01 1.14 1.14 0.76 1.48 1.37 1.75 -0.19 1.53 1.49 1.95
Total Cost of Revenue
0.00 0.00 0.00 - 0.00 0.00 0.00 - 0.00 0.00 0.00
Total Operating Expenses
13 17 14 15 16 15 19 17 19 18 20
Selling, General & Admin Expense
6.40 7.69 6.28 6.31 6.45 6.77 8.23 6.13 8.12 7.24 7.20
Research & Development Expense
6.83 8.90 8.11 8.29 9.53 8.40 11 11 11 11 13
Total Other Income / (Expense), net
0.30 0.17 0.28 - -0.85 -0.94 -2.43 -0.53 -1.34 -8.43 14
Interest Expense
- - 0.03 - 1.26 1.29 1.31 - 1.32 6.86 3.09
Interest & Investment Income
0.30 0.17 0.31 - 0.34 0.23 0.21 2.69 0.13 0.40 0.65
Other Income / (Expense), net
- - 0.00 - 0.07 0.11 -1.32 - -0.15 -1.97 17
Basic Earnings per Share
($0.51) ($0.44) ($0.05) ($0.86) ($0.05) ($0.05) ($0.07) ($0.06) ($0.06) ($0.07) ($0.01)
Weighted Average Basic Shares Outstanding
257.29M 257.41M 278.17M 325.74M 292.00M 292.07M 304.00M 300.17M 327.54M 338.68M 339.21M
Diluted Earnings per Share
($0.51) ($0.44) ($0.05) ($0.86) ($0.05) ($0.05) ($0.07) ($0.06) ($0.06) ($0.07) ($0.01)
Weighted Average Diluted Shares Outstanding
257.29M 257.41M 278.17M 325.74M 292.00M 292.07M 304.00M 300.17M 327.54M 338.68M 339.21M
Weighted Average Basic & Diluted Shares Outstanding
257.33M 287.86M 291.32M 292.01M 292.03M 292.30M 312.32M 327.90M 338.52M 339.11M 339.31M

Annual Cash Flow Statements for Ocugen

This table details how cash moves in and out of Ocugen's business through operations, investing, and financing, using annual figures. All values are USD millions unless otherwise specified.

Metric 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025
Period end date 12/31/2015 12/31/2016 12/31/2017 12/31/2018 12/31/2019 12/31/2020 12/31/2021 12/31/2022 12/31/2023 12/31/2024 12/31/2025
Net Change in Cash & Equivalents
-28 0.99 -25 -4.52 5.82 17 71 -18 -38 19 -40
Net Cash From Operating Activities
-29 -26 -23 -12 -17 -15 -48 -60 -62 -42 -57
Net Cash From Continuing Operating Activities
-30 -26 -23 -12 -17 -15 -48 -60 -62 -42 -57
Net Income / (Loss) Continuing Operations
-32 -16 -26 -18 -20 -22 -58 -87 -63 -54 -68
Consolidated Net Income / (Loss)
-32 -16 -26 -18 -20 -22 -58 -87 -63 -54 -68
Depreciation Expense
1.61 1.67 1.53 0.05 0.06 0.10 0.23 0.48 0.70 1.97 2.39
Amortization Expense
- 0.00 0.05 - - - 0.00 -0.10 -0.18 0.02 1.36
Non-Cash Adjustments To Reconcile Net Income
1.23 -13 2.51 3.16 6.15 8.03 7.71 17 13 5.43 6.43
Changes in Operating Assets and Liabilities, net
-0.85 1.99 -0.71 3.38 -2.86 -1.02 2.49 9.58 -13 4.50 0.70
Net Cash From Investing Activities
-1.95 -0.32 -1.23 -0.08 -2.36 -0.31 -1.82 -17 3.08 -3.39 -0.31
Net Cash From Continuing Investing Activities
-1.95 -0.32 -1.23 -0.08 -2.36 -0.31 -1.82 -17 3.08 -3.39 -0.31
Purchase of Property, Plant & Equipment
-1.95 -0.32 -0.28 -0.08 -0.03 -0.31 -0.94 -4.46 -10 -3.39 -0.19
Other Investing Activities, net
- - - - 0.00 0.00 -0.75 0.76 0.00 0.00 -0.13
Net Cash From Financing Activities
4.37 27 -0.58 7.18 25 32 121 59 21 65 17
Net Cash From Continuing Financing Activities
4.37 27 -0.58 7.18 25 32 121 59 21 65 17
Repayment of Debt
-0.41 -0.58 -0.58 -0.10 -5.39 -5.63 0.00 -0.04 -0.07 -0.81 -1.00
Repurchase of Common Equity
- - - 0.00 -0.05 -1.48 -8.53 -0.55 -0.36 -2.89 -1.53
Issuance of Debt
- - - 7.30 6.80 0.92 0.00 0.50 0.50 30 0.00
Issuance of Common Equity
4.74 - 0.00 0.00 1.18 38 129 60 21 39 20
Effect of Exchange Rate Changes
- - - 0.00 - - 0.00 0.03 -0.01 0.03 0.01

Quarterly Cash Flow Statements for Ocugen

This table details how cash moves in and out of Ocugen's business through operations, investing, and financing, using quarterly figures. All values are USD millions unless otherwise specified.

Metric Q1 2024 Q2 2024 Q3 2024 Q4 2024 Q1 2025 Q2 2025 Q3 2025 Q4 2025 Q1 2026 Q2 2026 Q3 2026
Period end date 3/31/2024 6/30/2024 9/30/2024 12/31/2024 3/31/2025 6/30/2025 9/30/2025 12/31/2025 3/31/2026 6/30/2026 9/30/2026
Net Change in Cash & Equivalents
-13 -10 23 20 -21 -11 5.55 -14 13 68 -78
Net Cash From Operating Activities
-11 -9.91 -11 -10 -19 -11 -13 -14 -22 -12 -16
Net Cash From Continuing Operating Activities
-11 -9.91 -11 -10 -19 -11 -13 -14 -22 -14 -17
Net Income / (Loss) Continuing Operations
-12 -15 -13 -14 -15 -15 -20 -18 -19 -25 -3.60
Consolidated Net Income / (Loss)
-12 -15 -13 -14 -15 -15 -20 -18 -19 -25 -3.60
Depreciation Expense
0.18 0.58 0.61 0.60 0.60 0.93 0.95 -0.40 0.59 0.59 0.55
Amortization Expense
- - - - 0.31 - - - 0.38 1.92 0.78
Non-Cash Adjustments To Reconcile Net Income
2.71 2.77 -1.59 2.17 1.35 0.70 2.01 2.36 2.74 3.41 -17
Changes in Operating Assets and Liabilities, net
-1.56 2.02 2.68 0.75 -6.27 2.38 4.17 0.42 -6.33 5.07 2.93
Net Cash From Investing Activities
-2.35 -0.51 -0.51 -0.01 -0.10 -0.09 -0.09 -0.04 -0.01 -0.02 -60
Net Cash From Continuing Investing Activities
-2.35 -0.51 -0.51 -0.01 -0.10 -0.09 -0.09 -0.04 -0.01 -0.02 -60
Purchase of Property, Plant & Equipment
-2.35 -0.51 -0.51 -0.01 -0.02 -0.04 -0.09 -0.04 -0.01 -0.02 -0.15
Net Cash From Financing Activities
-0.15 0.05 35 30 -1.25 0.06 19 0.00 35 80 0.16
Net Cash From Continuing Financing Activities
-0.15 0.05 35 30 -1.25 0.06 19 0.00 35 80 0.16
Repayment of Debt
0.00 - -2.89 -0.81 -1.00 - - - 0.00 -37 -0.02
Issuance of Common Equity
- - - 0.98 0.00 - - 1.53 23 0.68 0.18

Annual Balance Sheets for Ocugen

This table presents Ocugen's assets and liabilities at the end of each period, using annual balance sheet data. All values are USD millions unless otherwise specified.

Metric 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025
Period end date 12/31/2015 12/31/2016 12/31/2017 12/31/2018 12/31/2019 12/31/2020 12/31/2021 12/31/2022 12/31/2023 12/31/2024 12/31/2025
Total Assets
37 36 11 2.45 17 27 106 109 65 82 44
Total Current Assets
31 32 8.18 1.94 16 26 103 98 43 62 24
Cash & Equivalents
31 32 7.08 1.63 7.44 24 95 78 39 59 19
Short-Term Investments
- 0.00 0.90 - - - 0.00 13 - - 0.00
Prepaid Expenses
0.32 0.17 0.19 0.31 1.32 1.84 7.69 7.56 3.51 3.17 5.77
Plant, Property, & Equipment, net
5.21 3.86 2.72 0.25 0.22 0.63 1.16 6.05 17 17 14
Total Noncurrent Assets
0.34 0.14 0.14 0.27 0.82 0.87 1.95 4.09 4.29 4.21 4.78
Other Noncurrent Operating Assets
- - 0.00 0.27 0.82 0.87 1.95 4.09 4.29 4.21 4.78
Total Liabilities & Shareholders' Equity
37 36 11 2.45 17 27 106 109 65 82 44
Total Liabilities
8.59 23 22 15 5.79 5.83 9.94 35 24 53 56
Total Current Liabilities
6.36 5.17 3.81 14 4.54 3.61 7.00 29 17 22 23
Short-Term Debt
0.58 0.58 0.18 7.48 0.00 0.23 - - 0.00 1.33 1.25
Accounts Payable
3.80 1.95 0.78 3.28 1.90 0.40 2.31 8.06 3.17 4.24 6.20
Accrued Expenses
1.44 2.10 2.71 1.40 2.27 2.94 4.33 20 13 16 15
Other Current Liabilities
- - - 1.95 0.38 0.04 0.36 0.50 0.57 0.52 0.86
Total Noncurrent Liabilities
2.23 17 18 1.05 1.25 2.21 2.94 6.12 6.89 31 33
Long-Term Debt
0.76 0.18 - 1.02 1.07 1.82 1.71 2.29 2.80 27 28
Other Noncurrent Operating Liabilities
1.02 14 15 0.04 0.17 0.39 1.23 3.83 4.09 3.88 5.10
Commitments & Contingencies
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Equity & Noncontrolling Interests
28 14 -11 50 11 22 96 74 41 30 -12
Total Preferred & Common Equity
28 14 -11 -13 11 22 96 74 41 30 -12
Preferred Stock
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Common Equity
28 14 -11 50 11 22 96 74 41 30 -12
Common Stock
194 195 197 19 63 95 228 297 327 370 396
Retained Earnings
-166 -182 -208 -31 -51 -73 -132 -223 -286 -340 -408
Treasury Stock
- - - - -0.05 -0.05 -0.05 -0.05 -0.05 -0.05 -0.05
Accumulated Other Comprehensive Income / (Loss)
- 0.00 - 0.00 - - 0.00 0.03 0.02 0.05 0.06

Quarterly Balance Sheets for Ocugen

This table presents Ocugen's assets and liabilities at the end of each period, using quarterly balance sheet data. All values are USD millions unless otherwise specified.

Metric Q3 2023 Q1 2024 Q2 2024 Q3 2024 Q1 2025 Q2 2025 Q3 2025 Q1 2026 Q2 2026 Q3 2026
Period end date 9/30/2023 3/31/2024 6/30/2024 9/30/2024 3/31/2025 6/30/2025 9/30/2025 3/31/2026 6/30/2026 9/30/2026
Total Assets
75 52 41 62 64 54 58 57 124 108
Total Current Assets
57 30 19 41 44 33 38 39 107 91
Cash & Equivalents
53 26 16 39 38 27 33 32 100 25
Short-Term Investments
0.00 - - - - - - - - 60
Prepaid Expenses
3.08 3.62 2.92 1.98 6.16 5.87 5.07 6.70 6.67 7.17
Plant, Property, & Equipment, net
14 18 17 17 16 15 15 14 13 13
Total Noncurrent Assets
3.66 4.14 4.45 4.13 4.51 5.27 5.01 4.52 4.14 3.92
Other Noncurrent Operating Assets
3.66 4.14 4.45 4.13 4.51 5.27 5.01 4.52 4.14 3.92
Total Liabilities & Shareholders' Equity
75 52 41 62 64 54 58 57 124 108
Total Liabilities
16 22 24 21 49 51 54 51 141 126
Total Current Liabilities
11 16 18 16 17 18 20 21 133 119
Short-Term Debt
1.28 1.30 1.31 1.32 0.00 0.00 0.00 5.01 0.02 0.04
Accounts Payable
2.92 1.73 3.39 1.49 3.22 4.24 4.57 3.24 5.14 5.07
Accrued Expenses
6.40 12 13 12 13 13 15 12 11 13
Other Current Liabilities
0.54 0.59 0.46 0.48 0.74 0.85 0.86 0.85 117 101
Total Noncurrent Liabilities
5.16 5.48 5.64 5.54 32 33 34 30 7.68 6.84
Long-Term Debt
1.50 1.53 1.55 1.57 28 28 28 24 1.73 1.74
Other Noncurrent Operating Liabilities
3.66 3.95 4.09 3.97 3.99 4.53 5.30 6.20 5.95 5.10
Commitments & Contingencies
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Equity & Noncontrolling Interests
58 30 17 41 16 3.05 3.53 5.81 -17 -18
Total Preferred & Common Equity
58 30 17 41 16 3.05 3.53 5.81 -17 -18
Preferred Stock
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Common Equity
58 30 17 41 16 3.05 3.53 5.81 -17 -18
Common Stock
325 328 330 367 371 373 394 433 435 438
Retained Earnings
-267 -298 -313 -326 -356 -370 -390 -427 -452 -456
Treasury Stock
-0.05 -0.05 -0.05 -0.05 -0.05 -0.05 -0.05 -0.05 -0.05 -0.05
Accumulated Other Comprehensive Income / (Loss)
0.03 0.03 0.03 0.02 0.04 0.01 0.06 0.16 0.21 0.15

Annual Metrics And Ratios for Ocugen

This table displays calculated financial ratios and metrics derived from Ocugen's official financial filings.

Metric 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025
Period end date 12/31/2015 12/31/2016 12/31/2017 12/31/2018 12/31/2019 12/31/2020 12/31/2021 12/31/2022 12/31/2023 12/31/2024 12/31/2025
DEI Shares Outstanding
13,273,470.00 15,930,708.00 24,071,029.00 62,025,398.00 16,003,916.00 162,026,473.00 199,185,877.00 218,886,893.00 256,502,434.00 - 312,320,112.00
DEI Adjusted Shares Outstanding
221,225.00 265,512.00 401,184.00 1,033,757.00 16,003,916.00 162,026,473.00 199,185,877.00 218,886,893.00 256,502,434.00 - 312,320,112.00
DEI Earnings Per Adjusted Shares Outstanding
-144.76 -52.21 -56.08 -17.62 -1.26 -0.21 -0.29 -0.40 -0.25 - -0.22
Growth Metrics
- - - - - - - - - - -
Revenue Growth
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% -100.00% 0.00% 142.60% -32.82% 8.83%
EBITDA Growth
-38.44% 52.21% -72.44% 42.15% -27.53% -14.04% -177.10% -52.42% 26.70% 18.80% -13.67%
EBIT Growth
-40.90% 49.38% -64.40% 45.43% -27.52% -14.21% -176.84% -52.47% 26.43% 16.44% -16.41%
NOPAT Growth
2.58% 4.75% 17.68% 35.31% 12.25% -50.29% -172.62% -53.50% 26.43% 16.44% -14.90%
Net Income Growth
-40.50% 49.39% -62.97% 31.02% -11.11% -7.80% -167.46% -48.73% 27.33% 14.31% -25.52%
EPS Growth
64.67% 9.92% 54.59% 31.02% 60.22% 78.77% 3.23% -33.33% 35.00% -284.62% 77.00%
Operating Cash Flow Growth
-63.84% 12.43% 10.55% 49.48% -45.25% 12.93% -225.93% -25.32% -3.29% 32.09% -35.17%
Free Cash Flow Firm Growth
0.00% 65.71% -98.49% -35.40% 5.69% 51.85% -344.19% -3.42% -42.83% 46.90% -23.64%
Invested Capital Growth
44.24% -871.99% -10.16% 63.90% 179.60% -109.30% 695.37% -670.14% 126.61% -105.41% -821.80%
Revenue Q/Q Growth
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% -15.17% -13.72% -17.82%
EBITDA Q/Q Growth
-43.64% 54.56% -175.59% 44.55% 28.34% 34.08% -57.75% -18.40% 20.66% -3.73% -6.12%
EBIT Q/Q Growth
-41.71% 51.87% -148.93% 45.18% 28.24% 33.93% -57.53% -18.30% 20.43% -4.41% -6.39%
NOPAT Q/Q Growth
-5.91% 1.33% 6.98% 26.01% -38.28% 33.36% -56.49% -18.30% 20.43% -4.41% -5.28%
Net Income Q/Q Growth
-40.73% 51.79% -150.25% 33.36% 33.20% -286.21% -22.68% -17.31% 20.66% -5.69% -5.98%
EPS Q/Q Growth
-106.63% 13.83% -209.38% 33.36% 69.13% -138.46% -25.00% -11.11% 25.71% -488.24% -35.29%
Operating Cash Flow Q/Q Growth
-7.53% 3.17% 6.40% 11.65% -54.48% 23.27% -21.62% -7.34% 8.29% 2.18% -6.74%
Free Cash Flow Firm Q/Q Growth
0.00% -170.02% 57.70% -23.52% -349.24% 79.60% -50.74% 4.45% 7.12% -1.11% -16.29%
Invested Capital Q/Q Growth
-678.35% 55.78% -13.82% 51.22% 117.01% 71.75% 76.89% -263.51% -49.25% -104.38% -207.75%
Profitability Metrics
- - - - - - - - - - -
Gross Margin
0.00% 0.00% 0.00% 0.00% 0.00% 100.00% 0.00% 100.00% 100.00% 100.00% 100.00%
EBITDA Margin
0.00% 0.00% 0.00% 0.00% 0.00% -48,834.88% 0.00% -3,564.71% -1,077.02% -1,301.82% -1,355.74%
Operating Margin
0.00% 0.00% 0.00% 0.00% 0.00% -49,500.00% 0.00% -3,580.02% -1,085.67% -1,350.36% -1,425.70%
EBIT Margin
0.00% 0.00% 0.00% 0.00% 0.00% -49,072.09% 0.00% -3,580.02% -1,085.67% -1,350.36% -1,440.74%
Profit (Net Income) Margin
0.00% 0.00% 0.00% 0.00% 0.00% -50,748.84% 0.00% -3,488.91% -1,045.03% -1,333.02% -1,537.41%
Tax Burden Percent
99.97% 100.00% 100.00% 100.00% 100.00% 100.00% 99.91% 97.45% 96.26% 98.72% 100.00%
Interest Burden Percent
100.42% 100.37% 99.50% 125.75% 109.57% 103.42% 100.00% 100.00% 100.00% 100.00% 106.71%
Effective Tax Rate
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Invested Capital (ROIC)
0.00% 0.00% 0.00% 0.00% 0.00% -707.06% 0.00% 0.00% 0.00% -2,076.94% 0.00%
ROIC Less NNEP Spread (ROIC-NNEP)
0.00% 0.00% 0.00% 0.00% 0.00% -658.23% 0.00% 0.00% 0.00% -2,029.65% 0.00%
Return on Net Nonoperating Assets (RNNOA)
0.00% 0.00% 0.00% 0.00% 0.00% 573.05% 0.00% 0.00% 0.00% 1,922.93% 0.00%
Return on Equity (ROE)
-77.72% -77.62% -2,297.87% -94.66% -66.61% -134.01% -99.46% -102.24% -110.14% -154.01% -776.89%
Cash Return on Invested Capital (CROIC)
0.00% 0.00% 0.00% 0.00% -438.99% 0.00% -1,696.10% 0.00% -1,651.40% 0.00% 0.00%
Operating Return on Assets (OROA)
0.00% 0.00% 0.00% 0.00% 0.00% -95.52% 0.00% -83.09% -75.68% -74.50% -100.95%
Return on Assets (ROA)
0.00% 0.00% 0.00% 0.00% 0.00% -98.78% 0.00% -80.98% -72.85% -73.55% -107.73%
Return on Common Equity (ROCE)
-77.72% -77.62% -2,297.87% -94.66% -66.61% -134.01% -99.46% -102.24% -110.13% -154.01% -776.89%
Return on Equity Simple (ROE_SIMPLE)
-113.57% -119.47% 234.42% 143.35% -183.72% -101.26% -60.91% -117.33% -155.50% -182.42% 0.00%
Net Operating Profit after Tax (NOPAT)
-22 -21 -17 -11 -9.91 -15 -41 -62 -46 -38 -44
NOPAT Margin
0.00% 0.00% 0.00% 0.00% 0.00% -34,650.00% 0.00% -2,506.02% -759.97% -945.25% -997.99%
Net Nonoperating Expense Percent (NNEP)
-22.51% 17.28% -54.00% -22.88% -33.33% -48.83% -30.80% -26.89% -27.46% -47.29% -242.63%
Return On Investment Capital (ROIC_SIMPLE)
- - - - - - - - -105.78% -65.74% -264.89%
Cost of Revenue to Revenue
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
SG&A Expenses to Revenue
0.00% 0.00% 0.00% 0.00% 0.00% 18,544.19% 0.00% 1,422.83% 530.05% 658.10% 624.95%
R&D to Revenue
0.00% 0.00% 0.00% 0.00% 0.00% 31,055.81% 0.00% 2,257.19% 655.62% 792.26% 900.75%
Operating Expenses to Revenue
0.00% 0.00% 0.00% 0.00% 0.00% 49,600.00% 0.00% 3,680.02% 1,185.67% 1,450.36% 1,525.70%
Earnings before Interest and Taxes (EBIT)
-32 -16 -27 -14 -18 -21 -58 -89 -66 -55 -64
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)
-30 -14 -25 -14 -18 -21 -58 -89 -65 -53 -60
Valuation Ratios
- - - - - - - - - - -
Price to Book Value (P/BV)
1.65 1.96 0.00 0.11 0.76 13.76 9.46 3.85 3.64 7.91 0.00
Price to Tangible Book Value (P/TBV)
1.66 1.96 0.00 0.11 0.76 13.76 9.46 3.85 3.64 7.91 0.00
Price to Revenue (P/Rev)
0.00 0.00 0.00 0.00 0.00 6,895.55 0.00 114.37 24.43 57.83 95.54
Price to Earnings (P/E)
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Dividend Yield
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Earnings Yield
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Enterprise Value to Invested Capital (EV/IC)
0.00 0.00 0.00 0.00 0.42 0.00 316.12 0.00 28.40 0.00 0.00
Enterprise Value to Revenue (EV/Rev)
0.00 0.00 0.00 0.00 0.00 6,384.34 0.00 78.74 18.36 50.47 97.86
Enterprise Value to EBITDA (EV/EBITDA)
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to EBIT (EV/EBIT)
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to NOPAT (EV/NOPAT)
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to Operating Cash Flow (EV/OCF)
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to Free Cash Flow (EV/FCFF)
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Leverage & Solvency
- - - - - - - - - - -
Debt to Equity
0.05 0.06 -0.02 0.17 0.10 0.10 0.02 0.03 0.07 0.97 -2.37
Long-Term Debt to Equity
0.03 0.01 0.00 0.02 0.10 0.08 0.02 0.03 0.07 0.92 -2.26
Financial Leverage
-1.05 -1.39 -14.42 -1.57 -1.02 -0.87 -0.98 -1.07 -1.09 -0.95 -1.12
Leverage Ratio
1.24 1.74 20.49 0.35 0.32 1.36 1.13 1.26 1.51 2.09 7.21
Compound Leverage Factor
1.25 1.75 20.39 0.44 0.35 1.40 1.13 1.26 1.51 2.09 7.70
Debt to Total Capital
4.55% 5.31% -1.61% 14.59% 8.87% 8.71% 1.76% 3.00% 6.46% 49.18% 173.17%
Short-Term Debt to Total Capital
1.97% 4.07% -1.61% 12.84% 0.00% 0.99% 0.00% 0.00% 0.00% 2.27% 7.52%
Long-Term Debt to Total Capital
2.58% 1.24% 0.00% 1.75% 8.87% 7.72% 1.76% 3.00% 6.46% 46.90% 165.66%
Preferred Equity to Total Capital
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Noncontrolling Interests to Total Capital
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Common Equity to Total Capital
95.45% 94.69% 101.61% 85.41% 91.13% 91.29% 98.24% 97.00% 93.54% 50.82% -73.17%
Debt to EBITDA
-0.04 -0.05 -0.01 -0.59 -0.06 -0.10 -0.03 -0.03 -0.04 -0.54 -0.48
Net Debt to EBITDA
0.98 2.15 0.31 -0.48 0.35 1.05 1.60 1.00 0.56 0.57 -0.17
Long-Term Debt to EBITDA
-0.03 -0.01 0.00 -0.07 -0.06 -0.09 -0.03 -0.03 -0.04 -0.52 -0.46
Debt to NOPAT
-0.06 -0.04 -0.01 -0.75 -0.11 -0.14 -0.04 -0.04 -0.06 -0.75 -0.65
Net Debt to NOPAT
1.33 1.47 0.45 -0.61 0.64 1.48 2.30 1.42 0.80 0.78 -0.23
Long-Term Debt to NOPAT
-0.03 -0.01 0.00 -0.09 -0.11 -0.12 -0.04 -0.04 -0.06 -0.71 -0.63
Altman Z-Score
-5.11 -6.93 -32.55 -43.03 -6.25 25.22 52.21 0.14 -5.29 -4.67 -13.27
Noncontrolling Interest Sharing Ratio
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Liquidity Ratios
- - - - - - - - - - -
Current Ratio
4.91 6.20 2.15 0.14 3.47 7.16 14.66 3.45 2.51 2.86 1.06
Quick Ratio
4.86 6.17 2.10 0.12 1.64 6.65 13.57 3.19 2.31 2.71 0.81
Cash Flow Metrics
- - - - - - - - - - -
Free Cash Flow to Firm (FCFF)
-23 -8.05 -16 -22 -20 -9.82 -44 -45 -64 -34 -42
Operating Cash Flow to CapEx
-1,507.95% -8,042.50% -8,340.58% -15,023.82% -56,310.00% -4,791.21% -5,105.54% -1,347.97% -592.34% -1,244.96% -30,791.35%
Free Cash Flow to Firm to Interest Expense
-176.48 0.00 0.00 -5.77 -11.54 -13.62 0.00 0.00 0.00 0.00 -8.15
Operating Cash Flow to Interest Expense
-220.98 0.00 0.00 -3.10 -9.55 -20.40 0.00 0.00 0.00 0.00 -10.98
Operating Cash Flow Less CapEx to Interest Expense
-235.63 0.00 0.00 -3.12 -9.57 -20.83 0.00 0.00 0.00 0.00 -11.02
Efficiency Ratios
- - - - - - - - - - -
Asset Turnover
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.02 0.07 0.06 0.07
Accounts Receivable Turnover
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Inventory Turnover
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Fixed Asset Turnover
0.00 0.00 0.00 0.00 0.00 0.10 0.00 0.69 0.52 0.24 0.29
Accounts Payable Turnover
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Days Sales Outstanding (DSO)
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Days Inventory Outstanding (DIO)
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Days Payable Outstanding (DPO)
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Cash Conversion Cycle (CCC)
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Capital & Investment Metrics
- - - - - - - - - - -
Invested Capital
-1.51 -15 -16 -5.84 4.65 -0.43 2.57 -15 3.90 -0.21 -1.95
Invested Capital Turnover
0.00 0.00 0.00 0.00 0.00 0.02 0.00 -0.41 -1.12 2.20 -4.09
Increase / (Decrease) in Invested Capital
1.20 -13 -1.49 10 10 -5.08 3.00 -17 19 -4.11 -1.73
Enterprise Value (EV)
17 -4.54 42 12 1.95 275 813 196 111 205 432
Market Capitalization
46 27 49 5.48 8.32 297 906 285 147 235 422
Book Value per Share
$2.12 $0.85 ($0.47) $0.80 $0.69 $0.13 $0.48 $0.34 $0.16 $0.10 ($0.04)
Tangible Book Value per Share
$2.11 $0.85 ($0.47) $0.80 $0.69 $0.13 $0.48 $0.34 $0.16 $0.10 ($0.04)
Total Capital
30 14 -11 58 12 24 98 76 43 58 17
Total Debt
1.34 0.76 0.18 8.50 1.07 2.06 1.71 2.29 2.80 29 29
Total Long-Term Debt
0.76 0.18 0.00 1.02 1.07 1.82 1.71 2.29 2.80 27 28
Net Debt
-30 -31 -7.80 6.87 -6.37 -22 -93 -89 -37 -30 10
Capital Expenditures (CapEx)
1.95 0.32 0.28 0.08 0.03 0.31 0.94 4.46 10 3.39 0.19
Debt-free, Cash-free Net Working Capital (DFCFNWC)
-5.46 -4.42 -3.43 -6.31 3.78 -1.54 0.69 -21 -14 -17 -16
Debt-free Net Working Capital (DFNWC)
25 27 4.55 -4.68 11 22 96 70 26 41 2.55
Net Working Capital (NWC)
25 27 4.37 -12 11 22 96 70 26 40 1.30
Net Nonoperating Expense (NNE)
9.75 -5.01 8.95 6.92 10 6.92 18 24 17 16 24
Net Nonoperating Obligations (NNO)
-30 -28 -4.90 -56 -6.37 -22 -93 -89 -37 -30 10
Total Depreciation and Amortization (D&A)
1.61 1.67 1.59 0.05 0.06 0.10 0.23 0.38 0.52 1.97 3.75
Debt-free, Cash-free Net Working Capital to Revenue
0.00% 0.00% 0.00% 0.00% 0.00% -3,583.72% 0.00% -842.97% -224.98% -421.55% -363.11%
Debt-free Net Working Capital to Revenue
0.00% 0.00% 0.00% 0.00% 0.00% 52,320.93% 0.00% 2,811.94% 428.79% 1,021.46% 57.72%
Net Working Capital to Revenue
0.00% 0.00% 0.00% 0.00% 0.00% 51,776.74% 0.00% 2,811.94% 428.79% 988.75% 29.39%
Earnings Adjustments
- - - - - - - - - - -
Adjusted Basic Earnings per Share
($145.20) ($58.20) ($59.40) ($13.80) ($1.46) ($0.31) ($0.30) ($0.38) ($0.26) ($1.00) ($0.23)
Adjusted Weighted Average Basic Shares Outstanding
221.24K 237.62K 377.83K 606.64K 52.63M 188.09M 195.01M 214.60M 244.33M 325.74M 300.17M
Adjusted Diluted Earnings per Share
($145.20) ($130.80) ($59.40) ($47.40) ($1.46) ($0.31) ($0.30) ($0.38) ($0.26) ($1.00) ($0.23)
Adjusted Weighted Average Diluted Shares Outstanding
221.24K 239.82K 377.83K 618.17K 52.63M 188.09M 195.01M 214.60M 244.33M 325.74M 300.17M
Adjusted Basic & Diluted Earnings per Share
($145.20) ($58.20) $0.00 ($13.80) ($1.46) ($0.31) $0.00 $0.00 $0.00 $0.00 $0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding
220.52K 369.47K 478.12K 1.58M 13.89M 112.24M 199.49M 226.42M 0.00 292.01M 327.90M
Normalized Net Operating Profit after Tax (NOPAT)
-22 -21 -17 -11 -9.91 -15 -41 -62 -46 -38 -44
Normalized NOPAT Margin
0.00% 0.00% 0.00% 0.00% 0.00% -34,650.00% 0.00% -2,506.02% -759.97% -945.25% -997.99%
Pre Tax Income Margin
0.00% 0.00% 0.00% 0.00% 0.00% -50,748.84% 0.00% -3,580.02% -1,085.67% -1,350.36% -1,537.41%
Debt Service Ratios
- - - - - - - - - - -
EBIT to Interest Expense
-239.86 0.00 0.00 -3.86 -10.45 -29.27 0.00 0.00 0.00 0.00 -12.26
NOPAT to Interest Expense
-167.47 0.00 0.00 -3.01 -5.61 -20.67 0.00 0.00 0.00 0.00 -8.49
EBIT Less CapEx to Interest Expense
-254.52 0.00 0.00 -3.88 -10.47 -29.69 0.00 0.00 0.00 0.00 -12.29
NOPAT Less CapEx to Interest Expense
-182.12 0.00 0.00 -3.03 -5.62 -21.09 0.00 0.00 0.00 0.00 -8.52
Payout Ratios
- - - - - - - - - - -
Dividend Payout Ratio
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Augmented Payout Ratio
0.00% 0.00% 0.00% 0.00% -0.24% -6.77% -14.61% -0.63% -0.56% -5.34% -2.25%

Quarterly Metrics And Ratios for Ocugen

This table displays calculated financial ratios and metrics derived from Ocugen's official financial filings.

Metric Q1 2024 Q2 2024 Q3 2024 Q4 2024 Q1 2025 Q2 2025 Q3 2025 Q4 2025 Q1 2026 Q2 2026 Q3 2026
Period end date 3/31/2024 6/30/2024 9/30/2024 12/31/2024 3/31/2025 6/30/2025 9/30/2025 12/31/2025 3/31/2026 6/30/2026 9/30/2026
DEI Shares Outstanding
256,502,434.00 257,328,085.00 287,857,769.00 - 292,014,470.00 292,031,295.00 292,304,736.00 312,320,112.00 327,897,296.00 338,521,856.00 339,110,401.00
DEI Adjusted Shares Outstanding
256,502,434.00 257,328,085.00 287,857,769.00 - 292,014,470.00 292,031,295.00 292,304,736.00 312,320,112.00 327,897,296.00 338,521,856.00 339,110,401.00
DEI Earnings Per Adjusted Shares Outstanding
-0.05 -0.06 -0.05 - -0.05 -0.05 -0.07 -0.06 -0.06 -0.07 -0.01
Growth Metrics
- - - - - - - - - - -
Revenue Growth
128.89% 135.26% -69.29% -45.78% 46.06% 20.33% 54.23% -125.26% 3.51% 8.38% 11.36%
EBITDA Growth
33.14% 36.46% -3.13% -16.71% -12.38% 13.47% -42.38% -31.34% -25.84% -24.75% 100.93%
EBIT Growth
32.27% 34.37% -6.60% -20.09% -18.17% 10.71% -42.96% -22.80% -24.61% -34.59% 93.89%
NOPAT Growth
32.27% 34.37% -6.60% -20.09% -18.71% 10.71% -33.00% -22.80% -23.02% -19.20% -0.73%
Net Income Growth
31.18% 33.75% -10.69% -26.53% -28.73% 3.54% -54.60% -27.56% -24.93% -68.78% 82.06%
EPS Growth
-537.50% -340.00% 0.00% -2,766.67% 90.20% 88.64% -40.00% 0.00% -20.00% -40.00% 85.71%
Operating Cash Flow Growth
41.91% 47.30% 17.76% 8.30% -82.70% -8.26% -14.58% -34.71% -12.59% -13.68% -21.86%
Free Cash Flow Firm Growth
-26.95% 31.02% 68.62% 79.07% 33.55% 22.70% -7.43% -82.29% -6.83% 1,215.09% 1,365.17%
Invested Capital Growth
382.05% 67.47% -37.30% -105.41% -13.88% -0.59% -113.11% -821.80% -45.63% -2,926.23% -15,748.10%
Revenue Q/Q Growth
-28.03% 12.52% -0.44% -32.75% 93.85% -7.29% 27.60% -111.02% 894.30% -2.94% 31.12%
EBITDA Q/Q Growth
-6.09% -23.54% 15.02% -4.77% -2.15% 5.33% -39.84% 3.35% 2.13% 6.53% 101.06%
EBIT Q/Q Growth
-6.00% -26.47% 14.23% -4.44% -4.31% 4.87% -37.33% 10.29% -5.85% -2.36% 93.72%
NOPAT Q/Q Growth
-6.00% -26.47% 14.22% -4.44% -4.78% 4.87% -27.76% 3.57% -4.97% 7.82% -7.96%
Net Income Q/Q Growth
-8.70% -28.14% 15.12% -7.02% -10.59% 3.98% -36.04% 11.70% -8.31% -29.72% 85.54%
EPS Q/Q Growth
-1,600.00% 13.73% 88.64% -1,620.00% 0.00% 0.00% -40.00% 14.29% 0.00% -16.67% 85.71%
Operating Cash Flow Q/Q Growth
6.26% 6.46% -13.73% 8.06% -86.77% 44.57% -20.37% -8.09% -56.11% 44.03% -29.03%
Free Cash Flow Firm Q/Q Growth
47.91% 10.18% 48.57% 13.00% -65.36% -4.49% 28.53% -47.61% 3.09% 1,190.66% -18.91%
Invested Capital Q/Q Growth
72.09% -39.12% 17.93% -104.38% 2,840.76% -29.73% -115.55% -207.75% 261.65% -3,753.24% 12.80%
Profitability Metrics
- - - - - - - - - - -
Gross Margin
100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 0.00% 100.00% 100.00% 100.00%
EBITDA Margin
-1,187.08% -1,303.33% -1,112.50% -1,733.25% -913.37% -937.22% -1,027.05% 0.00% -1,110.37% -1,069.29% 8.61%
Operating Margin
-1,204.73% -1,353.99% -1,166.55% -1,811.52% -979.14% -1,004.73% -1,005.99% 0.00% -1,163.67% -1,105.11% -909.94%
EBIT Margin
-1,204.73% -1,353.99% -1,166.46% -1,811.52% -974.75% -1,004.73% -1,081.28% 0.00% -1,173.45% -1,237.43% -59.30%
Profit (Net Income) Margin
-1,175.94% -1,339.18% -1,141.73% -1,816.75% -1,036.46% -1,073.49% -1,144.46% 0.00% -1,250.95% -1,671.84% -184.42%
Tax Burden Percent
100.08% 100.03% 100.00% 100.29% 100.00% 99.23% 100.00% 101.02% 100.00% 100.00% 100.00%
Interest Burden Percent
97.53% 98.88% 97.88% 100.00% 106.33% 107.67% 105.84% 103.13% 106.60% 135.11% 310.98%
Effective Tax Rate
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Invested Capital (ROIC)
-1,374.39% -2,108.69% -613.58% -2,786.23% -495.98% -820.30% -1,805.46% 0.00% -814.84% 0.00% 0.00%
ROIC Less NNEP Spread (ROIC-NNEP)
-1,367.50% -2,097.62% -605.04% -2,773.63% -465.10% -734.36% -1,766.86% 0.00% -710.25% 0.00% 0.00%
Return on Net Nonoperating Assets (RNNOA)
1,262.96% 1,940.57% 528.61% 2,627.79% 339.21% 434.72% 1,599.27% 0.00% 418.32% 0.00% 0.00%
Return on Equity (ROE)
-111.43% -168.11% -84.97% -158.45% -156.76% -385.59% -206.19% -776.89% -396.52% 1,211.66% 923.92%
Cash Return on Invested Capital (CROIC)
-1,162.32% -1,157.35% -541.03% 0.00% -624.06% -950.63% 0.00% 0.00% -979.92% 0.00% 0.00%
Operating Return on Assets (OROA)
-107.50% -151.86% -80.26% -99.95% -75.83% -101.48% -97.15% 0.00% -86.34% -63.75% -3.42%
Return on Assets (ROA)
-104.93% -150.19% -78.55% -100.24% -80.63% -108.43% -102.83% 0.00% -92.04% -86.13% -10.64%
Return on Common Equity (ROCE)
-111.43% -168.11% -84.97% -158.45% -156.76% -385.59% -206.19% -776.89% -396.52% 1,211.66% 923.92%
Return on Equity Simple (ROE_SIMPLE)
-190.60% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Net Operating Profit after Tax (NOPAT)
-8.55 -11 -9.28 -9.69 -10 -9.66 -12 -12 -12 -12 -12
NOPAT Margin
-843.31% -947.79% -816.58% -1,268.06% -685.40% -703.31% -704.20% 0.00% -814.57% -773.58% -636.96%
Net Nonoperating Expense Percent (NNEP)
-6.89% -11.07% -8.54% -12.61% -30.88% -85.95% -38.59% -59.21% -104.59% -27.48% 20.38%
Return On Investment Capital (ROIC_SIMPLE)
-25.84% -54.66% -21.32% -16.62% -23.29% -31.07% -38.64% -71.55% -35.68% 77.74% 78.14%
Cost of Revenue to Revenue
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
SG&A Expenses to Revenue
631.56% 673.79% 552.82% 826.44% 435.72% 492.79% 469.63% 0.00% 529.48% 486.69% 369.25%
R&D to Revenue
673.18% 780.19% 713.73% 1,085.08% 643.42% 611.94% 636.36% 0.00% 734.18% 718.41% 640.70%
Operating Expenses to Revenue
1,304.73% 1,453.99% 1,266.55% 1,911.52% 1,079.14% 1,104.73% 1,105.99% 0.00% 1,263.67% 1,205.11% 1,009.94%
Earnings before Interest and Taxes (EBIT)
-12 -15 -13 -14 -14 -14 -19 -17 -18 -18 -1.16
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)
-12 -15 -13 -13 -14 -13 -18 -17 -17 -16 0.17
Valuation Ratios
- - - - - - - - - - -
Price to Book Value (P/BV)
13.90 23.56 7.03 7.91 12.96 92.85 134.86 0.00 102.24 0.00 0.00
Price to Tangible Book Value (P/TBV)
13.90 23.56 7.03 7.91 12.96 92.85 134.86 0.00 102.24 0.00 0.00
Price to Revenue (P/Rev)
63.67 54.92 60.77 57.83 45.61 59.61 88.73 95.54 132.92 113.09 73.09
Price to Earnings (P/E)
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Dividend Yield
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Earnings Yield
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Enterprise Value to Invested Capital (EV/IC)
59.14 94.43 51.82 0.00 33.91 69.98 0.00 0.00 187.92 0.00 0.00
Enterprise Value to Revenue (EV/Rev)
60.11 53.15 53.15 50.47 43.37 59.82 87.95 97.86 132.33 91.62 55.83
Enterprise Value to EBITDA (EV/EBITDA)
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to EBIT (EV/EBIT)
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to NOPAT (EV/NOPAT)
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to Operating Cash Flow (EV/OCF)
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to Free Cash Flow (EV/FCFF)
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 5.94 5.21
Leverage & Solvency
- - - - - - - - - - -
Debt to Equity
0.09 0.17 0.07 0.97 1.74 9.18 8.04 -2.37 5.03 -0.11 -0.10
Long-Term Debt to Equity
0.05 0.09 0.04 0.92 1.74 9.18 8.04 -2.26 4.17 -0.10 -0.10
Financial Leverage
-0.92 -0.93 -0.87 -0.95 -0.73 -0.59 -0.91 -1.12 -0.59 7.20 6.12
Leverage Ratio
1.40 1.49 1.38 2.09 2.52 4.71 2.71 7.21 5.59 -13.17 -11.71
Compound Leverage Factor
1.36 1.47 1.35 2.09 2.68 5.07 2.86 7.44 5.96 -17.79 -36.41
Debt to Total Capital
8.55% 14.45% 6.63% 49.18% 63.49% 90.18% 88.94% 173.17% 83.41% -11.81% -11.18%
Short-Term Debt to Total Capital
3.92% 6.60% 3.02% 2.27% 0.00% 0.00% 0.00% 7.52% 14.30% -0.14% -0.22%
Long-Term Debt to Total Capital
4.63% 7.84% 3.61% 46.90% 63.49% 90.18% 88.94% 165.66% 69.11% -11.68% -10.96%
Preferred Equity to Total Capital
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Noncontrolling Interests to Total Capital
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Common Equity to Total Capital
91.45% 85.55% 93.37% 50.82% 36.51% 9.82% 11.06% -73.17% 16.59% 111.81% 111.18%
Debt to EBITDA
-0.05 -0.06 -0.06 -0.54 -0.51 -0.54 -0.50 -0.48 -0.46 -0.03 -0.04
Net Debt to EBITDA
0.40 0.25 0.70 0.57 0.19 -0.02 0.07 -0.17 0.04 1.48 1.71
Long-Term Debt to EBITDA
-0.03 -0.03 -0.03 -0.52 -0.51 -0.54 -0.50 -0.46 -0.38 -0.03 -0.04
Debt to NOPAT
-0.07 -0.08 -0.08 -0.75 -0.69 -0.72 -0.68 -0.65 -0.63 -0.04 -0.04
Net Debt to NOPAT
0.56 0.36 0.98 0.78 0.25 -0.03 0.10 -0.23 0.06 2.04 1.71
Long-Term Debt to NOPAT
-0.04 -0.04 -0.04 -0.71 -0.69 -0.72 -0.68 -0.63 -0.52 -0.04 -0.04
Altman Z-Score
3.34 -1.75 0.52 -3.03 -5.34 -6.74 -4.83 -9.74 -4.13 -3.60 -4.53
Noncontrolling Interest Sharing Ratio
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Liquidity Ratios
- - - - - - - - - - -
Current Ratio
1.87 1.04 2.58 2.86 2.60 1.83 1.85 1.06 1.86 0.80 0.77
Quick Ratio
1.64 0.87 2.46 2.71 2.24 1.50 1.60 0.81 1.54 0.75 0.71
Cash Flow Metrics
- - - - - - - - - - -
Free Cash Flow to Firm (FCFF)
-14 -12 -6.41 -5.58 -9.22 -9.63 -6.88 -10 -9.85 107 87
Operating Cash Flow to CapEx
-450.47% -1,931.97% -2,223.27% -79,723.08% -120,981.25% -24,953.49% -14,193.41% -39,888.57% -363,233.33% -58,085.71% -10,563.09%
Free Cash Flow to Firm to Interest Expense
0.00 0.00 -220.98 0.00 -7.33 0.00 -5.24 0.00 -7.46 15.66 28.19
Operating Cash Flow to Interest Expense
0.00 0.00 -388.69 0.00 -15.40 0.00 -9.83 0.00 -16.51 -1.78 -5.09
Operating Cash Flow Less CapEx to Interest Expense
0.00 0.00 -406.17 0.00 -15.41 0.00 -9.90 0.00 -16.52 -1.78 -5.14
Efficiency Ratios
- - - - - - - - - - -
Asset Turnover
0.09 0.11 0.07 0.06 0.08 0.10 0.09 0.07 0.07 0.05 0.06
Accounts Receivable Turnover
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Inventory Turnover
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Fixed Asset Turnover
0.52 0.50 0.30 0.24 0.27 0.29 0.33 0.29 0.30 0.32 0.35
Accounts Payable Turnover
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Days Sales Outstanding (DSO)
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Days Inventory Outstanding (DIO)
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Days Payable Outstanding (DPO)
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Cash Conversion Cycle (CCC)
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Capital & Investment Metrics
- - - - - - - - - - -
Invested Capital
6.72 4.09 4.82 -0.21 5.78 4.06 -0.63 -1.95 3.14 -115 -100
Invested Capital Turnover
1.63 2.22 0.75 2.20 0.72 1.17 2.56 -4.09 1.00 -0.08 -0.09
Increase / (Decrease) in Invested Capital
5.32 1.65 -2.87 -4.11 -0.93 -0.02 -5.45 -1.73 -2.64 -119 -100
Enterprise Value (EV)
397 386 250 205 196 284 472 432 591 420 267
Market Capitalization
421 399 286 235 206 283 476 422 593 518 349
Book Value per Share
$0.12 $0.07 $0.14 $0.10 $0.05 $0.01 $0.01 ($0.04) $0.02 ($0.05) ($0.05)
Tangible Book Value per Share
$0.12 $0.07 $0.14 $0.10 $0.05 $0.01 $0.01 ($0.04) $0.02 ($0.05) ($0.05)
Total Capital
33 20 44 58 44 31 32 17 35 -15 -16
Total Debt
2.83 2.86 2.89 29 28 28 28 29 29 1.75 1.78
Total Long-Term Debt
1.53 1.55 1.57 27 28 28 28 28 24 1.73 1.74
Net Debt
-24 -13 -36 -30 -10 1.01 -4.17 10 -2.66 -98 -82
Capital Expenditures (CapEx)
2.35 0.51 0.51 0.01 0.02 0.04 0.09 0.04 0.01 0.02 0.15
Debt-free, Cash-free Net Working Capital (DFCFNWC)
-11 -14 -12 -17 -11 -12 -15 -16 -9.01 -126 -112
Debt-free Net Working Capital (DFNWC)
15 1.95 26 41 27 15 17 2.55 23 -26 -27
Net Working Capital (NWC)
14 0.65 25 40 27 15 17 1.30 18 -26 -27
Net Nonoperating Expense (NNE)
3.37 4.47 3.69 4.19 5.20 5.08 7.71 5.81 6.69 13 -8.83
Net Nonoperating Obligations (NNO)
-24 -13 -36 -30 -10 1.01 -4.17 10 -2.66 -98 -82
Total Depreciation and Amortization (D&A)
0.18 0.58 0.61 0.60 0.91 0.93 0.95 -0.40 0.97 2.50 1.33
Debt-free, Cash-free Net Working Capital to Revenue
-168.47% -189.26% -265.30% -421.55% -237.11% -254.92% -284.67% -363.11% -201.72% -2,759.61% -2,337.23%
Debt-free Net Working Capital to Revenue
230.73% 26.86% 558.02% 1,021.46% 598.81% 313.29% 321.75% 57.72% 511.71% -575.09% -574.16%
Net Working Capital to Revenue
211.11% 8.88% 530.02% 988.75% 598.81% 313.29% 321.75% 29.39% 399.62% -575.52% -574.89%
Earnings Adjustments
- - - - - - - - - - -
Adjusted Basic Earnings per Share
($0.05) ($0.04) ($0.05) ($0.86) ($0.05) ($0.05) ($0.07) ($0.06) ($0.06) ($0.07) ($0.01)
Adjusted Weighted Average Basic Shares Outstanding
257.23M 257.35M 278.17M 325.74M 292.00M 292.07M 304.00M 300.17M 327.54M 338.68M 339.21M
Adjusted Diluted Earnings per Share
($0.05) ($0.04) ($0.05) ($0.86) ($0.05) ($0.05) ($0.07) ($0.06) ($0.06) ($0.07) ($0.01)
Adjusted Weighted Average Diluted Shares Outstanding
257.23M 257.35M 278.17M 325.74M 292.00M 292.07M 304.00M 300.17M 327.54M 338.68M 339.21M
Adjusted Basic & Diluted Earnings per Share
$0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding
257.33M 287.86M 291.32M 292.01M 292.03M 292.30M 312.32M 327.90M 338.52M 339.11M 339.31M
Normalized Net Operating Profit after Tax (NOPAT)
-8.55 -11 -9.28 -9.69 -10 -9.66 -12 -12 -12 -12 -12
Normalized NOPAT Margin
-843.31% -947.79% -816.58% -1,268.06% -685.40% -703.31% -704.20% 0.00% -814.57% -773.58% -636.96%
Pre Tax Income Margin
-1,174.95% -1,338.83% -1,141.73% -1,811.52% -1,036.46% -1,081.79% -1,144.46% 0.00% -1,250.95% -1,671.84% -184.42%
Debt Service Ratios
- - - - - - - - - - -
EBIT to Interest Expense
0.00 0.00 -456.93 0.00 -11.48 0.00 -14.42 0.00 -13.63 -2.68 -0.37
NOPAT to Interest Expense
0.00 0.00 -319.88 0.00 -8.08 0.00 -9.39 0.00 -9.46 -1.68 -4.02
EBIT Less CapEx to Interest Expense
0.00 0.00 -474.41 0.00 -11.50 0.00 -14.49 0.00 -13.63 -2.69 -0.42
NOPAT Less CapEx to Interest Expense
0.00 0.00 -337.36 0.00 -8.09 0.00 -9.46 0.00 -9.46 -1.68 -4.07
Payout Ratios
- - - - - - - - - - -
Dividend Payout Ratio
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Augmented Payout Ratio
-0.57% -0.47% 0.00% -5.34% -4.77% -5.22% 0.00% -2.25% -4.61% -4.04% -5.06%

Financials Breakdown Chart

Key Financial Trends

Ocugen’s Q2 2026 statements show improved liquidity, but the company remains unprofitable and dependent on external financing. Revenue was $1.5 million, down slightly from $1.5 million in Q1 2026 but up from $1.4 million in Q2 2025. Despite reporting no cost of revenue, operating expenses reached $17.9 million, including $10.7 million in research and development. The company posted a $24.9 million net loss, compared with losses of $19.2 million in Q1 2026 and $14.7 million in Q2 2025.

Cash and equivalents increased to $100.1 million at June 30, 2026, from $31.9 million at the end of Q1 and $27.0 million a year earlier. However, this improvement was primarily supported by financing activity rather than operations. Operating cash flow remained negative at $12.2 million in Q2, following a $21.8 million outflow in Q1 and a $14.0 million outflow in Q4 2025. A simple comparison of the cash balance with the latest quarterly operating burn suggests several quarters of liquidity, but the estimate does not account for debt obligations, working-capital needs or future financing requirements.

The balance sheet has deteriorated materially. Total liabilities rose to $140.8 million from $51.1 million a year earlier, while shareholders’ equity turned negative at $16.6 million from positive equity of $3.1 million in Q2 2025. Current liabilities of $133.1 million exceeded current assets of $106.7 million, producing a current ratio below 1.0. The company also appears to be using equity financing regularly: weighted-average basic shares increased to approximately 338.7 million in Q2 2026 from 292.1 million in Q2 2025, creating dilution for existing shareholders.

  • Cash reserves improved substantially: Cash reached $100.1 million in Q2 2026, up approximately $68.2 million during the quarter and about $73.0 million year over year.
  • Operating cash burn improved sequentially: Cash used in operations declined to $12.2 million in Q2 from $21.8 million in Q1 2026, although it remains significant.
  • Revenue remains relatively consistent: Quarterly revenue has generally remained between roughly $1.0 million and $1.8 million over the reported periods, with Q2 2026 revenue increasing about 8% from Q2 2025.
  • Capital spending is limited: Purchases of property and equipment were only $21,000 in Q2 2026, reducing near-term investment-related cash demands.
  • Research and development spending remains elevated: R&D expense was $10.7 million in Q2, indicating continued investment in the pipeline but also requiring substantial funding before commercial success is demonstrated.
  • Reported gross margins require caution: Ocugen reported zero cost of revenue and gross profit equal to revenue, but the small revenue base and biotechnology-focused business model make this margin profile difficult to interpret as a measure of recurring profitability.
  • Losses are widening: The Q2 2026 net loss of $24.9 million was larger than the losses reported in Q1 2026, Q2 2025 and most earlier comparable quarters.
  • The company has not achieved operating profitability: Operating losses have remained substantial, reaching $16.4 million in Q2 2026 despite only $1.5 million of revenue.
  • Liquidity is heavily dependent on financing: Q2 cash growth was driven by financing activity while operating activities consumed $12.2 million, raising the risk of additional capital raises.
  • Balance-sheet risk and dilution have increased: Total liabilities exceeded total assets at quarter-end, producing negative equity, while weighted-average shares rose approximately 16% year over year.
11/16/26 10:48 AM ETAI Generated. May Contain Errors.

Ocugen Financials - Frequently Asked Questions

According to the most recent income statement we have on file, Ocugen's fiscal year ends in December. Their fiscal year 2025 ended on December 31, 2025.

Ocugen's net income appears to be on a downward trend, with a most recent value of -$67.85 million in 2025, falling from -$32.02 million in 2015. The previous period was -$54.05 million in 2024. Find out what analysts predict for Ocugen in the coming months.

Ocugen's total operating income in 2025 was -$62.92 million, based on the following breakdown:
  • Total Gross Profit: $4.41 million
  • Total Operating Expenses: $67.33 million

Over the last 10 years, Ocugen's total revenue changed from $0.00 in 2015 to $4.41 million in 2025, a change of 441,300,000.0%.

In the past 12 quarters, Ocugen's cash and equivalents has ranged from $15.70 million in Q2 2024 to $100.05 million in Q2 2026, and is currently $24.63 million as of their latest financial filing in Q3 2026.

Ocugen had total debt of $28.79 million at the end of 2025, a 0.4% increase from 2024, and a 2,042.3% increase since 2015.

Over the last 10 years, Ocugen's book value per share changed from 2.12 in 2015 to -0.04 in 2025.



Financial statements for NASDAQ:OCGN last updated on 11/4/2026 by MarketBeat.com Staff. New filings and market data are monitored continuously.
From Our Partners